These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 23247660)
1. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Terwey TH; Le Duc TM; Hemmati PG; le Coutre P; Nagy M; Martus P; Dörken B; Arnold R Ann Oncol; 2013 May; 24(5):1363-70. PubMed ID: 23247660 [TBL] [Abstract][Full Text] [Related]
2. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220 [TBL] [Abstract][Full Text] [Related]
3. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia. Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100 [TBL] [Abstract][Full Text] [Related]
4. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Yeshurun M; Weisdorf D; Rowe JM; Tallman MS; Zhang MJ; Wang HL; Saber W; de Lima M; Sandmaier BM; Uy G; Kamble RT; Cairo MS; Cooper BW; Cahn JY; Ganguly S; Camitta B; Verdonck LF; Dandoy C; Diaz MA; Savani BN; George B; Liesveld J; McGuirk J; Byrne M; Grunwald MR; Drobyski WR; Pulsipher MA; Abdel-Azim H; Prestidge T; Wieduwilt MJ; Martino R; Norkin M; Beitinjaneh A; Seo S; Nishihori T; Wirk B; Frangoul H; Bashey A; Mori S; Marks DI; Bachanova V Blood Adv; 2019 Feb; 3(4):670-680. PubMed ID: 30808685 [TBL] [Abstract][Full Text] [Related]
5. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes. Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380 [TBL] [Abstract][Full Text] [Related]
6. [Clinical study on the relapsd leukemia patients with graft versus host disease after allogeneic hematopoietic stem cell transplantation]. Zhang XH; Fu HX; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Zhao T; Wang Y; Chen Y; Huang XJ Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):323-7. PubMed ID: 21122312 [TBL] [Abstract][Full Text] [Related]
7. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136 [TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481 [TBL] [Abstract][Full Text] [Related]
9. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788 [TBL] [Abstract][Full Text] [Related]
10. [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia]. Wojnar J; Giebel S; Hołowiecka-Goral A; Krawczyk-Kuliś M; Markiewicz M; Stella-Hołowiecka B; Wylezoł I Pol Arch Med Wewn; 2006 Jul; 116(1):671-7. PubMed ID: 17340974 [TBL] [Abstract][Full Text] [Related]
11. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation]. Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470 [No Abstract] [Full Text] [Related]
12. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Zecca M; Prete A; Rondelli R; Lanino E; Balduzzi A; Messina C; Fagioli F; Porta F; Favre C; Pession A; Locatelli F; Blood; 2002 Aug; 100(4):1192-200. PubMed ID: 12149197 [TBL] [Abstract][Full Text] [Related]
13. [Impact of graft versus host disease on outcome of allogeneic peripherial blood stem cell transplantation for leukemia]. Li M; Zhang W; Wang J; Song X; Yang J; Ni X; Yang D; Chen L; Chen J; Hu X; Gao L; Qiu H; Zhou H; Cheng H Zhonghua Xue Ye Xue Za Zhi; 2014 May; 35(5):428-33. PubMed ID: 24857214 [TBL] [Abstract][Full Text] [Related]
14. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E; Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175 [TBL] [Abstract][Full Text] [Related]
15. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study. Itonaga H; Iwanaga M; Aoki K; Aoki J; Ishiyama K; Ishikawa T; Sakura T; Fukuda T; Najima Y; Yujiri T; Mori T; Kurokawa M; Nawa Y; Uchida N; Morishita Y; Hashimoto H; Eto T; Hirokawa M; Morishima Y; Nagamura-Inoue T; Atsuta Y; Miyazaki Y Leuk Res; 2016 Feb; 41():48-55. PubMed ID: 26754557 [TBL] [Abstract][Full Text] [Related]
16. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907 [TBL] [Abstract][Full Text] [Related]
17. What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease? Ringdén O; Labopin M; Sadeghi B; Mailhol A; Beelen D; Fløisand Y; Ghavamzadeh A; Finke J; Ehninger G; Volin L; Socié G; Kröger N; Stuhler G; Ganser A; Schmid C; Giebel S; Mohty M; Nagler A J Intern Med; 2018 Feb; 283(2):166-177. PubMed ID: 29027756 [TBL] [Abstract][Full Text] [Related]
18. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Sairafi D; Remberger M; Uhlin M; Ljungman P; Ringdén O; Mattsson J Biol Blood Marrow Transplant; 2010 Dec; 16(12):1728-37. PubMed ID: 20542125 [TBL] [Abstract][Full Text] [Related]
19. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Thepot S; Zhou J; Perrot A; Robin M; Xhaard A; de Latour RP; Ades L; Ribaud P; Petropoulou AD; Porcher R; Socié G Leukemia; 2010 Nov; 24(11):1852-8. PubMed ID: 20827288 [TBL] [Abstract][Full Text] [Related]